Physician profile
Jeffrey Weiser
NPI 1437253051
$4,274.69
in general payments reported to CMS, 2019-2025
35 companies · $1,161 in 2025
The $1,161 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $960 · 2020: $109 · 2022: $214 · 2023: $604 · 2024: $1,226 · 2025: $1,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,949 · Education: $41.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,949.31 |
| Education | $41.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,073.35 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $492.01 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $412.50 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $378.87 | 2019-2025 | Stelara, Tremfya |
| Genzyme Corporation | $225.17 | 2023-2024 | |
| Lilly USA, LLC | $196.76 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $187.37 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $168.73 | 2023-2025 | Ocaliva |
| Pfizer INC. | $163.09 | 2024 | |
| Qol Medical, LLC | $124.94 | 2024-2025 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $109.18 | 2022-2023 | |
| Celgene Corporation | $74.29 | 2022-2024 | Zeposia |
| Ardelyx, INC. | $73.55 | 2023-2025 | Ibsrela |
| Medtronic, INC. | $63.79 | 2024 | Barrx |
| Shire North American Group INC | $61.38 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $60.71 | 2019 | |
| Ironwood Pharmaceuticals, INC | $45.25 | 2019-2024 | |
| Gilead Sciences, INC. | $31.67 | 2019-2022 | |
| Allergan, INC. | $30.85 | 2019 | |
| Novo Nordisk INC | $30.62 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $29.54 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.98 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.60 | 2023 | Cyltezo |
| Phathom Pharmaceuticals, INC. | $20.82 | 2024 | Voquezna |
| Exact Sciences Corporation | $19.86 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $19.08 | 2019 | |
| Romark Laboratories, Lc | $18.84 | 2019 | |
| Endo Pharmaceuticals INC. | $18.60 | 2019 | |
| Braintree Laboratories, INC. | $18.16 | 2019 | |
| Ucb, INC. | $17.07 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $16.78 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.14 | 2022 | |
| Alfasigma USA, INC. | $14.00 | 2020 | |
| Shionogi INC | $12.14 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Weiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.